ABBVMEDIUM SIGNALFINANCIAL10-K

AbbVie delivered substantially higher operating income while reducing share repurchases and expanding its balance sheet footprint.

The meaningful expansion in operating profitability suggests strong underlying business momentum, likely driven by continued growth in newer immunology assets like Rinvoq and Skyrizi as Humira biosimilar headwinds stabilize. The shift from aggressive share buybacks to increased capital expenditure indicates management is prioritizing reinvestment in the business over returning cash to shareholders.

Comparing 2026-02-20 vs 2025-02-14View on EDGAR →
FINANCIAL ANALYSIS

AbbVie's financial profile improved markedly with operating income growing substantially while the company modestly reduced share repurchases and increased capital spending. The balance sheet expanded across key working capital metrics including inventory, receivables, and current assets, suggesting growing business activity. Overall, the financial picture points to a company generating stronger profitability while investing more heavily in future growth rather than financial engineering.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+65%
$9.1B→$15.1B

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Share Buybacks
Cash Flow
-42.6%
$1.7B→$980.0M

Buyback activity reduced 42.6% — capital being redeployed elsewhere or cash conservation underway.

Capital Expenditure
Cash Flow
+24.6%
$974.0M→$1.2B

Capex increased 24.6% — ongoing investment in capacity or infrastructure for future growth.

Inventory
Balance Sheet
+18.4%
$4.2B→$5.0B

Inventory built 18.4% — monitor whether demand supports this build or if write-downs may follow.

Accounts Receivable
Balance Sheet
+15.3%
$10.9B→$12.6B

Receivables grew 15.3% — monitor days sales outstanding for collection efficiency.

Current Assets
Balance Sheet
+13.6%
$25.6B→$29.1B

Current assets grew 13.6% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
+11.7%
$38.7B→$43.3B

Current liabilities rose 11.7% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-20
PRIOR — 2025-02-14
ADDED
AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics.
In the United States, Rinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis, moderate to severe ulcerative colitis and moderate to severe active Crohn's disease in adult patients who have an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
For Crohn's disease and ulcerative colitis, it is additionally approved prior to the use of TNF blockers in patients for whom the use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy.
It is also indicated for the treatment of adult and pediatric patients two years of age and older with active psoriatic arthritis and for the treatment of patients two years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
It is also indicated for the treatment of adults and adolescents 12 years of age and older with moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
+7 more — sign up free →
REMOVED
AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, oncology, aesthetics, neuroscience and eye care.
Humira is sold in numerous other markets worldwide, including Japan, China, Brazil and Australia.
Skyrizi is approved in multiple countries globally, including the United States, Canada and the European Union, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
In psoriatic disease (psoriasis or psoriatic arthritis), Skyrizi is administered as a quarterly subcutaneous injection following two induction doses.
In the United States, Rinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis, for active psoriatic arthritis in adults and children 2 years of age and older, for moderate to severe active ulcerative colitis, for active ankylosing spondylitis and for active non-radiographic axial spondyloarthritis in adult patients who have an inadequate response or intolerance to one or more TNF blockers.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →